All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
23Apr19 11:27 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35 EQS Basilea Pharmaceutica 0.40% Health 819.1m Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10 EQS Basilea Pharmaceutica 0.40% Health 819.1m Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports significantly improved financial results in 2017
23Feb18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17 EQS Basilea Pharmaceutica 0.40% Health 819.1m Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea names new member of its Extended Management Committee
27Apr17 17:32 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea names new member of its Extended Management Committee
02Dec16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea provides clinical program updates
18Dec15 17:42 GNW Basilea Pharmaceutica 0.40% Health 819.1m Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea launches a senior convertible bond issue
05Nov15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15 GNW Basilea Pharmaceutica 0.40% Health 819.1m Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Date / Time Source Company % Chg
23Apr19 11:27 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35 EQS Basilea Pharmaceutica 0.40%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06 GNW Basilea Pharmaceutica 0.40%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10 EQS Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports significantly improved financial results in 2017
23Feb18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15 GNW Basilea Pharmaceutica 0.40%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17 EQS Basilea Pharmaceutica 0.40%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea names new member of its Extended Management Committee
27Apr17 17:32 GNW Basilea Pharmaceutica 0.40%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15 GNW Basilea Pharmaceutica 0.40%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea names new member of its Extended Management Committee
02Dec16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30 GNW Basilea Pharmaceutica 0.40%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15 GNW Basilea Pharmaceutica 0.40%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea provides clinical program updates
18Dec15 17:42 GNW Basilea Pharmaceutica 0.40%
Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36 GNW Basilea Pharmaceutica 0.40%
Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea launches a senior convertible bond issue
05Nov15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43 GNW Basilea Pharmaceutica 0.40%
Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48 GNW Basilea Pharmaceutica 0.40%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15 GNW Basilea Pharmaceutica 0.40%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Date / Time Company % Chg
23Apr19 11:27 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 Basilea Pharmaceutica 0.40%
Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
14Aug18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports half-year financial results reflecting strong in-market product sales growth in addition to progress and expansion of the R&D pipeline
13Aug18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports on first Cresemba® approval in MENA region
09Aug18 06:15 Basilea Pharmaceutica 0.40%
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
19Jul18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports receipt of milestone payment based on first Cresemba® approval in Latin America
16Jul18 10:35 Basilea Pharmaceutica 0.40%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
26Jun18 06:15 Basilea Pharmaceutica 0.40%
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
05Jun18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting
15May18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
04May18 10:44 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Derazantinib deal adds third oncology asset
27Apr18 06:15 Basilea Pharmaceutica 0.40%
Basilea announces appointment of Chief Technology Officer and appointment of Head of Global Quality Management
20Apr18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports presentations of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
18Apr18 17:06 Basilea Pharmaceutica 0.40%
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders
18Apr18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
17Apr18 06:15 Basilea Pharmaceutica 0.40%
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
09Apr18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
19Mar18 11:10 Basilea Pharmaceutica 0.40%
Basilea Pharmaceutica AG (BSLN-CH): Reaping the rewards of an intense BD period
06Mar18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
01Mar18 06:15 Basilea Pharmaceutica 0.40%
Basilea names Adesh Kaul as new member of its Management Committee
27Feb18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports significantly improved financial results in 2017
23Feb18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
21Feb18 06:15 Basilea Pharmaceutica 0.40%
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
10Jan18 06:15 Basilea Pharmaceutica 0.40%
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
03Jan18 06:15 Basilea Pharmaceutica 0.40%
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
21Dec17 06:15 Basilea Pharmaceutica 0.40%
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
01Dec17 06:15 Basilea Pharmaceutica 0.40%
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
02Nov17 06:15 Basilea Pharmaceutica 0.40%
Basilea reports on commercial progress of antifungal Cresemba® in Europe
31Oct17 06:15 Basilea Pharmaceutica 0.40%
Basilea's Chief Medical Officer Prof. Achim Kaufhold to retire and Dr. Marc Engelhardt named as successor
23Oct17 06:15 Basilea Pharmaceutica 0.40%
Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
11Oct17 13:17 Basilea Pharmaceutica 0.40%
Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
28Sep17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
12Sep17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Cardiome to commercialize antibiotic Zevtera®/Mabelio® (ceftobiprole) in Europe and Israel
10Aug17 06:15 Basilea Pharmaceutica 0.40%
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
20Jul17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
14Jun17 18:15 Basilea Pharmaceutica 0.40%
Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel
14Jun17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada
13Jun17 06:15 Basilea Pharmaceutica 0.40%
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
12Jun17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
06Jun17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
02Jun17 06:15 Basilea Pharmaceutica 0.40%
Basilea names new member of its Extended Management Committee
27Apr17 17:32 Basilea Pharmaceutica 0.40%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15 Basilea Pharmaceutica 0.40%
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15 Basilea Pharmaceutica 0.40%
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15 Basilea Pharmaceutica 0.40%
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15 Basilea Pharmaceutica 0.40%
Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15 Basilea Pharmaceutica 0.40%
Basilea names new member of its Extended Management Committee
02Dec16 06:15 Basilea Pharmaceutica 0.40%
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
15Nov16 06:15 Basilea Pharmaceutica 0.40%
Basilea's antifungal Cresemba® (isavuconazole) launched in France
20Sep16 06:15 Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
15Sep16 06:15 Basilea Pharmaceutica 0.40%
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
13Sep16 06:15 Basilea Pharmaceutica 0.40%
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
06Sep16 06:15 Basilea Pharmaceutica 0.40%
Basilea starts continuous infusion phase 1/2a clinical study with oncology drug candidate BAL101553
17Aug16 06:15 Basilea Pharmaceutica 0.40%
Basilea announces distribution agreement with Hikma for CRESEMBA® (isavuconazole) in the MENA region
15Aug16 06:15 Basilea Pharmaceutica 0.40%
Basilea reports 2016 half-year results - CRESEMBA® launched in key European markets
27Jun16 06:15 Basilea Pharmaceutica 0.40%
Basilea's antifungal CRESEMBA® (isavuconazole) launched in Italy
09Jun16 06:15 Basilea Pharmaceutica 0.40%
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
21Apr16 17:30 Basilea Pharmaceutica 0.40%
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
20Apr16 06:15 Basilea Pharmaceutica 0.40%
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
15Apr16 06:15 Basilea Pharmaceutica 0.40%
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
15Mar16 06:15 Basilea Pharmaceutica 0.40%
Basilea issues agenda for Annual General Meeting of Shareholders
09Mar16 06:15 Basilea Pharmaceutica 0.40%
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
04Mar16 06:15 Basilea Pharmaceutica 0.40%
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
03Mar16 06:15 Basilea Pharmaceutica 0.40%
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
29Feb16 06:15 Basilea Pharmaceutica 0.40%
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
21Jan16 20:15 Basilea Pharmaceutica 0.40%
GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program
29Dec15 06:15 Basilea Pharmaceutica 0.40%
Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor
28Dec15 06:15 Basilea Pharmaceutica 0.40%
Basilea provides clinical program updates
18Dec15 17:42 Basilea Pharmaceutica 0.40%
Final allocations of Basilea CHF 200 million senior convertible bonds
09Dec15 17:36 Basilea Pharmaceutica 0.40%
Basilea successfully places CHF 200 million senior convertible bonds
09Dec15 06:15 Basilea Pharmaceutica 0.40%
Basilea launches a senior convertible bond issue
05Nov15 06:15 Basilea Pharmaceutica 0.40%
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
23Oct15 06:15 Basilea Pharmaceutica 0.40%
Basilea announces that European Commission maintained isavuconazole's orphan drug status
16Oct15 19:43 Basilea Pharmaceutica 0.40%
Basilea announces filing of registration statement for a proposed offering in the United States
16Oct15 15:48 Basilea Pharmaceutica 0.40%
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
15Oct15 06:15 Basilea Pharmaceutica 0.40%
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
12Oct15 06:15 Basilea Pharmaceutica 0.40%
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections